| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/IJD.13543 |
| P698 | PubMed publication ID | 28181669 |
| P50 | author | Petr Arenberger | Q12044794 |
| Martina Kojanová | Q57916492 | ||
| Spyridon Gkalpakiotis | Q58119752 | ||
| Petra Cetkovská | Q73465704 | ||
| Jorga Fialová | Q84146454 | ||
| Jitka Jircikova | Q125310055 | ||
| P2093 | author name string | Tomas Dolezal | |
| BIOREP study group | |||
| P2860 | cites work | Psoriasis prevalence among adults in the United States | Q46308366 |
| Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study | Q46625469 | ||
| Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. | Q48695846 | ||
| Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. | Q53125208 | ||
| Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis | Q57950827 | ||
| Global epidemiology of psoriasis: a systematic review of incidence and prevalence | Q26991871 | ||
| Challenges for synthesising data in a network of registries for systemic psoriasis therapies | Q34296816 | ||
| Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q34545044 | ||
| Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. | Q34558876 | ||
| The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. | Q34730794 | ||
| Genetic Epidemiology of Psoriasis | Q34845927 | ||
| Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest | Q36275101 | ||
| National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. | Q37027264 | ||
| Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey | Q37268881 | ||
| Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. | Q37506748 | ||
| The association between psoriasis and dyslipidaemia: a systematic review | Q38056160 | ||
| The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies | Q38064779 | ||
| Incidence and risk factors for psoriasis in the general population | Q38458971 | ||
| Use of biologics for psoriasis in Central and Eastern European countries | Q38586836 | ||
| Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. | Q39004998 | ||
| Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice. | Q40539910 | ||
| High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study | Q40988865 | ||
| Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis | Q43280124 | ||
| Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry | Q44377041 | ||
| Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. | Q44769660 | ||
| Psoriasis and hypertension: a case-control study. | Q44969254 | ||
| Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. | Q46191430 | ||
| National registries of systemic treatment for psoriasis and the European 'Psonet' initiative | Q46200779 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 428-434 | |
| P577 | publication date | 2017-02-09 | |
| P1433 | published in | International Journal of Dermatology | Q15752742 |
| P1476 | title | Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries | |
| P478 | volume | 56 |
| Q47586627 | A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions |
| Q48123615 | Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. |
| Q47606183 | Systemic Inflammation, Oxidative Damage to Nucleic Acids, and Metabolic Syndrome in the Pathogenesis of Psoriasis |
| Q61447254 | Type 2 diabetes and psoriasis: links and risks |
Search more.